Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
5.83
0.07 (1.22%)
At close: Jan 14, 2022 4:00 PM
6.15
0.32 (5.49%)
After-hours:Jan 14, 2022 7:59 PM EST
Market Cap600.51M
Revenue (ttm)2.12M
Net Income (ttm)-102.99M
Shares Out103.00M
EPS (ttm)-2.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume414,386
Open5.72
Previous Close5.76
Day's Range5.57 - 5.86
52-Week Range5.57 - 17.45
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About HUMA

Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded...

IndustryBiotechnology
Founded2004
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolHUMA
Full Company Profile

Financial Performance

Financial Statements

News

Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatmen...

DURHAM, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

1 week ago - GlobeNewsWire

Humacyte Announces Presentation of First Preclinical Results of the HAV™ in Coronary Artery Bypass Grafting at Advanc...

DURHAM, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

1 week ago - GlobeNewsWire

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

2 weeks ago - GlobeNewsWire

Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Con...

-- Vanderbilt University Medical Center patient received the HAV under the U.S. Food and Drug Administration's (FDA) Expanded Access Program (EAP) in April 2019 -- -- After replacement, the patient resu...

1 month ago - GlobeNewsWire

Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at Ame...

-- Patency and host cell remodeling of the HAV were observed in all study implants –

1 month ago - GlobeNewsWire

Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System

– Performance of HAVs produced in the LUNA200™  commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials –

2 months ago - GlobeNewsWire

Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights

-- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds -- -- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (H...

2 months ago - GlobeNewsWire

Humacyte Leadership to Present at Credit Suisse 30th Annual Healthcare Conference

DURHAM, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

2 months ago - GlobeNewsWire

Humacyte Leadership to Present at Multiple Scientific Events in November

DURHAM, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

2 months ago - GlobeNewsWire

Humacyte Leadership to Present at Seven Scientific and Industry Events in October

DURHAM, N.C., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

3 months ago - GlobeNewsWire

Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengi...

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercia...

3 months ago - GlobeNewsWire

Humacyte Leadership to Present at Five Scientific Events in September

DURHAM, N.C., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercia...

3 months ago - GlobeNewsWire

Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today a...

4 months ago - GlobeNewsWire

Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business...

NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a defini...

5 months ago - GlobeNewsWire

EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'

Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million.  Humacyte founder and ...

7 months ago - Benzinga

2 SPAC Stocks That Could Be 10-Baggers

They could even deliver greater gains than just a 10-times return.

10 months ago - The Motley Fool

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today ...

10 months ago - GlobeNewsWire

Should You Invest in Humacyte Before the SPAC Merger?

The biotech is going public through the special acquisition company (SPAC).

10 months ago - The Motley Fool

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International S...

DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today ...

10 months ago - GlobeNewsWire

Why Humacyte Is Going Public Via SPAC

Feb.17 -- Dr. Laura Niklason, chief executive officer and founder of Humacyte, discusses the biotech company's decision to go public through a merger with Alpha Healthcare Acquisition Corp., a special p...

10 months ago - Bloomberg Technology

Regenerative Tissue Developer Humacyte Going Public Via SPAC

Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.

10 months ago - The Motley Fool